Erasca Inc. (ERAS)
ERAS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ERAS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001761918 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $119.0M cash; operating cash flow -$27.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 350,956,416 (2026-11-05); 283,711,805 a year earlier; 151,087,038 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-07-14 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Diego, California, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$51.3M | -$32.7M | $119.0M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$44.1M | -$27.3M | $42.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$183.4M | -$27.4M | $47.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$29.1M | -$21.7M | $73.8M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | Not filed | -$30.6M | -$21.7M | $70.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$33.9M | -$20.5M | $66.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$31.0M | -$31.6M | $70.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$32.2M | -$24.6M | $67.7M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-14 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 357 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.7% |
| 1 month | +6.0% |
| 3 months | -12.3% |
| Year to date | +321.0% |
| 1 year | +516.5% |
| From 52-week high | -30.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
| LQDA | Liquidia Corporation | $56.37 | -1.81% | $5.1B |
| DNTH | Dianthus Therapeutics Inc. | $89.55 | -2.46% | $5.0B |
| EWTX | Edgewise Therapeutics Inc. | $43.68 | -4.90% | $4.8B |
| COGT | Cogent Biosciences Inc. | $27.44 | -3.92% | $4.8B |
| TVTX | Travere Therapeutics Inc. | $49.70 | -1.88% | $4.8B |
| MIRM | Mirum Pharmaceuticals Inc. | $91.58 | -2.56% | $6.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier